Curevac’s credibility unravels along with its Covid-19 vaccine
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
A broader use for Regeneron’s Covid-19 antibody combo
Casirivimab plus imdevimab could at last add a hospitalised Covid-19 patient treatment string to their bow.
Novavax's Prevent-19 lives up to its name
But with many Western markets already saturated, it is worth wondering how important Novavax’s Covid-19 jab will become.
Biopharma and venture capital: a deep dive
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
Curevac’s credibility unravels along with its Covid-19 vaccine
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
A broader use for Regeneron’s Covid-19 antibody combo
Casirivimab plus imdevimab could at last add a hospitalised Covid-19 patient treatment string to their bow.
Novavax's Prevent-19 lives up to its name
But with many Western markets already saturated, it is worth wondering how important Novavax’s Covid-19 jab will become.
Biopharma and venture capital: a deep dive
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
